MorphoSys Announces Re-election of Supervisory Board Members
May 18, 2006 02:13 ET | MorphoSys AG
MARTINSRIED, Germany, May 18, 2006 (PRIMEZONE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment:TecDAX) announced today that at the Company's annual shareholder meeting on Wednesday, May 17,...
Universal Detection Technology
Universal Detection Technology Completes the First Sale of BSM-2000 Anthrax Detector
May 17, 2006 09:00 ET | Universal Detection Technology
LOS ANGELES, May 17, 2006 (PRIMEZONE) -- Universal Detection Technology (OTCBB:UDTT) (FWB:PO8), a developer of early-warning monitoring technologies to protect people from bioterrorism and other...
Phase III Community-Acquired Pneumonia Study Opens for Basilea's Novel Broad-spectrum anti-MRSA Antibiotic Ceftobiprole to Broaden Indications
May 17, 2006 01:15 ET | Basilea Pharmaceutica AG
Basel, Switzerland, May 17, 2006   Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today the  initiation of a community-acquired pneumonia trial further expanding the development program...
Basilea schliesst die Rekrutierung in die Phase III Zulassungsstudie für Alitretinoin bei Patienten mit schwerer chronischer Handdermatitis ab.
May 17, 2006 01:15 ET | Basilea Pharmaceutica AG
Basel, 17. Mai, 2006   Basilea Pharmaceutica AG (SWX:BSLN) gab heute bekannt, dass die Rekrutierung f├╝r die BACH Studie (Benefit of Alitretinoin in Chronic Hand dermatitis) mit mehr als 1000...
Phase III Studienstart für ambulant erworbene Lungenentzündung erweitert die möglichen Anwendungen für Basileas neues Breitspektrum Anti-MRSA Antibiotikum Ceftobiprol
May 17, 2006 01:15 ET | Basilea Pharmaceutica AG
Basel, 17. Mai, 2006    Basilea Pharmaceutica AG (SWX:BSLN) gab heute den Beginn einer Studie von Ceftobiprol bei ambulant erworbener Lungenentz├╝ndung  bekannt. Diese Studie erweitert...
Basilea Completes Patient Recruitment of Alitretinoin Pivotal Phase III Study in Patients with Severe Chronic Hand Dermatitis.
May 17, 2006 01:15 ET | Basilea Pharmaceutica AG
Basel, Switzerland, May 17, 2006   Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today completion of recruitment of over 1000 patients in its BACH study (Benefit of Alitretinoin in Chronic...
Epigenomics AG Announces Continuation of Pharmaceutical Biomarker Research Collaboration with AstraZeneca in the Field of Oncology
May 16, 2006 09:16 ET | Epigenomics AG
BERLIN and SEATTLE, May 16, 2006 (PRIMEZONE) -- Epigenomics AG (Frankfurt:ECX) (Prime Standard:ECX), a molecular diagnostics company developing tests based on DNA methylation, announced today that the...
Bowe Group in the First Quarter 2006 On Growth Path
May 16, 2006 05:40 ET | BOWE SYSTEC AG
- Sales increased to 109.5 million Euro (+14.6 million Euro) - Order intake at 111.7 million Euro significantly up on previous year (+14.7 million Euro) - Net earnings negative as in...
Jerini AG Reports First Quarter Financial Results
May 15, 2006 04:50 ET | Jerini AG
BERLIN, May 15, 2006 (PRIMEZONE) -- Jerini AG (FSE:JI4) reported financial results for its first quarter ended March 31, 2006. Under International Financial Reporting Standards (IFRS), revenues for...
Crews Being Mobilized on Past Producing Lucky Boy Uranium Mine
May 15, 2006 03:01 ET | Golden Patriot Corp.
UNIONDALE, N.Y., May 15, 2006 (PRIMEZONE) -- Golden Patriot, Corp. ("GPTC") (OTCBB:GPTC) (Frankfurt:GPU) is pleased to announce that it has been informed by the operator (Ashex) of the project that...